This is a preview of subscription content, log in via an institution to check access.
References
Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377:454–464. https://doi.org/10.1056/NEJMoa1614359
Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Kindler T, Lübbert M, Wolf D, Westermann J, Kraemer D, Götze KS, Horst HA, Krauter J, Girschikofsky M, Ringhoffer M, Südhoff T, Held G, Derigs HG, Schroers R, Greil R, Grießhammer M, Lange E, Burchardt A, Martens U, Hertenstein B, Marretta L, Heuser M, Thol F, Gaidzik VI, Herr W, Krzykalla J, Benner A, Döhner K, Ganser A, Paschka P, Döhner H, German-Austrian AML Study Group (2019) Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood 133(840):851. https://doi.org/10.1182/blood-2018-08-869453
Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Dalle IA, Döhner H, Esteve J, Floisand Y, Giebel S, Gilleece M, Gorin NC, Jabbour E, Aljurf M, Kantarjian H, Kharfan-Dabaja M, Labopin M, Lanza F, Malard F, Peric Z, Prebet T, Ravandi F, Ruggeri A, Sanz J, Schmid C, Shouval R, Spyridonidis A, Versluis J, Vey N, Savani BN, Nagler A, Mohty M (2020) Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 105:1507–1516. https://doi.org/10.3324/haematol.2019.243410
Daver N, Venugopal S, Ravandi F (2021) FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J 11:104. https://doi.org/10.1038/s41408-021-00495-3
Döhner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, Prior TW, Marcucci G, Jones D, Krauter J, Heuser M, Voso MT, Ottone T, Nomdedeu JF, Mandrekar SJ, Klisovic RB, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte T, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Benner A, Pallaud C, Stone RM, Döhner H, Bloomfield CD (2020) Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood 135:371–380. https://doi.org/10.1182/blood.2019002697
Venditti A, Piciocchi A, Candoni A, Melillo L, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Luppi M, Mazza P, Martelli MP, Cuneo A, Albano F, Fabbiano F, Tafuri A, Chierichini A, Tieghi A, Fracchiolla NS, Capelli D, Foà R, Alati C, La Sala E, Fazi P, Vignetti M, Maurillo L, Buccisano F, Del Principe MI, Irno-Consalvo M, Ottone T, Lavorgna S, Voso MT, Lo-Coco F, Arcese W, Amadori S (2019) GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood 134:935–945. https://doi.org/10.1182/blood.2018886960
Pottinger B, Walker M, Campbell M, Holyoake TL, Franklin IM, Cook G (2002) The storage and re-infusion of autologous blood and BM as back-up following failed primary hematopoietic stem-cell transplantation: a survey of European practice. Cytotherapy 4:127–135. https://doi.org/10.1080/146532402317381839
Stelljes M, van Biezen A, Slavin S, Olavarria E, Clark RE, Nagler A, Koza V, Kienast J, Niederwieser D, de Witte T, Ruutu T, complications subcommittee of the Chronic Leukemia Working Party (2008) The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 42(739):742. https://doi.org/10.1038/bmt.2008.254
Stotler C, Bolwell B, Sobecks R, Dean R, Serafino S, Rybicki L, Andresen S, Pohlman B, Kalaycio M, Copelan E (2010) Are backup BM harvests worthwhile in unrelated donor allogeneic transplants? Bone Marrow Transplant 45:49–52. https://doi.org/10.1038/bmt.2009.95
Ferrara F, Palmieri S, Pollio F, Lo Pardo C, Graziano D, Celentano M, D’Amico MR, Vicari L, Izzo B, Pane F (2006) Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia. Biol Blood Marrow Transplant 12:981–986. https://doi.org/10.1016/j.bbmt.2006.05.017
Funding
This work was supported by grants from the Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy (IG 20624–2018) (ML); the Progetto di Eccellenza Dipartimento MIUR 2017 (ML); and the “Charity Dinner initiative” in memory of Dr A. Fontana for Associazione Italiana Lotta alle Leucemie, Linfoma e Mieloma (AIL) – Sezione ‘Luciano Pavarotti’– Modena OdV and IRIS Ceramica Group.
This work was also supported by grants from the Fondazione Regionale per la Ricerca Biomedica (PC), Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo di Pavia [Ricerca Corrente 08069113 and 08069119 (PC)], and Fondazione Just Italia (PC).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
FF served on advisory boards for Janssen and Novartis and received travel grants from Jazz Pharmaceuticals and Sanofi. ML served on advisory boards for Novartis, AbbVie, Jazz Pharmaceuticals, Gilead Sci., MSD, Sanofi, Daiichi-Sankyo, and Grifols and received travel grants from Gilead Sci and Sanofi. RobMar received research funding from Janssen and Gilead Sciences and honoraria from Gilead Sciences, Janssen, Abbvie, Roche, and Shire. The other authors have no competing interests to declare that are relevant to the content of this article.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Cordella, S., Parisotto, A., Bettelli, F. et al. Feasibility of autologous peripheral blood stem cell mobilization and harvest in adult patients with FLT3-mutated acute myeloid leukemia receiving chemotherapy combined with midostaurin: a single-center experience. Ann Hematol 102, 213–217 (2023). https://doi.org/10.1007/s00277-022-05013-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-022-05013-4